533 related articles for article (PubMed ID: 15603255)
1. Bacterial targets to antimicrobial leads and development candidates.
Rogers BL
Curr Opin Drug Discov Devel; 2004 Mar; 7(2):211-22. PubMed ID: 15603255
[TBL] [Abstract][Full Text] [Related]
2. Challenges of antibacterial discovery revisited.
Gwynn MN; Portnoy A; Rittenhouse SF; Payne DJ
Ann N Y Acad Sci; 2010 Dec; 1213():5-19. PubMed ID: 21058956
[TBL] [Abstract][Full Text] [Related]
3. Cell-division inhibitors: new insights for future antibiotics.
Lock RL; Harry EJ
Nat Rev Drug Discov; 2008 Apr; 7(4):324-38. PubMed ID: 18323848
[TBL] [Abstract][Full Text] [Related]
4. Late stage antibacterial drugs in the clinical pipeline.
Projan SJ; Bradford PA
Curr Opin Microbiol; 2007 Oct; 10(5):441-6. PubMed ID: 17950658
[TBL] [Abstract][Full Text] [Related]
5. Structure-based approaches to antibiotic drug discovery.
Nicola G; Abagyan R
Curr Protoc Microbiol; 2009 Feb; Chapter 17():Unit17.2. PubMed ID: 19235149
[TBL] [Abstract][Full Text] [Related]
6. Antibacterial drug discovery and structure-based design.
Barker JJ
Drug Discov Today; 2006 May; 11(9-10):391-404. PubMed ID: 16635801
[TBL] [Abstract][Full Text] [Related]
7. Exploiting current understanding of antibiotic action for discovery of new drugs.
Chopra I; Hesse L; O'Neill AJ
Symp Ser Soc Appl Microbiol; 2002; (31):4S-15S. PubMed ID: 12481824
[TBL] [Abstract][Full Text] [Related]
8. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
9. Exploiting current understanding of antibiotic action for discovery of new drugs.
Chopra I; Hesse L; O'Neill AJ
J Appl Microbiol; 2002; 92 Suppl():4S-15S. PubMed ID: 12000608
[TBL] [Abstract][Full Text] [Related]
10. Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: intelligent design and evolution through the judicious use of structure-guided design and structure-activity relationships.
Charifson PS; Grillot AL; Grossman TH; Parsons JD; Badia M; Bellon S; Deininger DD; Drumm JE; Gross CH; LeTiran A; Liao Y; Mani N; Nicolau DP; Perola E; Ronkin S; Shannon D; Swenson LL; Tang Q; Tessier PR; Tian SK; Trudeau M; Wang T; Wei Y; Zhang H; Stamos D
J Med Chem; 2008 Sep; 51(17):5243-63. PubMed ID: 18690678
[TBL] [Abstract][Full Text] [Related]
11. Crystallizing new approaches for antimicrobial drug discovery.
Schmid MB
Biochem Pharmacol; 2006 Mar; 71(7):1048-56. PubMed ID: 16458857
[TBL] [Abstract][Full Text] [Related]
12. Targeting non-multiplying organisms as a way to develop novel antimicrobials.
Coates AR; Hu Y
Trends Pharmacol Sci; 2008 Mar; 29(3):143-50. PubMed ID: 18262665
[TBL] [Abstract][Full Text] [Related]
13. New antimicrobial agents for the treatment of bacterial infections in cancer patients.
Rolston KV
Hematol Oncol; 2009 Sep; 27(3):107-14. PubMed ID: 19569253
[TBL] [Abstract][Full Text] [Related]
14. Novel heterodimer antibiotics: a review of recent patent literature.
Long DD; Marquess DG
Future Med Chem; 2009 Sep; 1(6):1037-50. PubMed ID: 21425993
[TBL] [Abstract][Full Text] [Related]
15. Small and lethal: searching for new antibacterial compounds with novel modes of action.
Pathania R; Brown ED
Biochem Cell Biol; 2008 Apr; 86(2):111-5. PubMed ID: 18443624
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway.
Lu H; Tonge PJ
Acc Chem Res; 2008 Jan; 41(1):11-20. PubMed ID: 18193820
[TBL] [Abstract][Full Text] [Related]
17. Natural products--the future scaffolds for novel antibiotics?
Butler MS; Buss AD
Biochem Pharmacol; 2006 Mar; 71(7):919-29. PubMed ID: 16289393
[TBL] [Abstract][Full Text] [Related]
18. Tigecycline: first of a new class of antimicrobial agents.
Rose WE; Rybak MJ
Pharmacotherapy; 2006 Aug; 26(8):1099-110. PubMed ID: 16863487
[TBL] [Abstract][Full Text] [Related]
19. Novel approaches to antimicrobial therapy: peptide deformylase.
Waller AS; Clements JM
Curr Opin Drug Discov Devel; 2002 Sep; 5(5):785-92. PubMed ID: 12630299
[TBL] [Abstract][Full Text] [Related]
20. Pleuromutilin derivatives having a purine ring. Part 1: new compounds with promising antibacterial activity against resistant Gram-positive pathogens.
Hirokawa Y; Kinoshita H; Tanaka T; Nakamura T; Fujimoto K; Kashimoto S; Kojima T; Kato S
Bioorg Med Chem Lett; 2008 Jun; 18(12):3556-61. PubMed ID: 18511280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
